LAURA B.

COMMERCIAL STRATEGY – SENIOR CONSULTANT

Laura’s 22 years of pharmaceutical and biotech commercialization success is based on collaborating with stakeholders to identify real differentiation for patients that also supports business requirements throughout all phases of development. Therapeutic experience includes: endocrine, cardiology, infectious disease, addiction, oncology, parenteral nutrition and respiratory, across acute, chronic, common and rare diseases.

Laura has worked on three continents and many countries, living abroad and across the United States, enabling her to effectively communicate across cultural barriers and understand fundamental differences of commercialization across regions. As a team member in big, mid-size and start-up pharma companies, consulting firms, public relations and advertising agencies, Laura has the expertise of applying best-in-class commercial planning practices regardless of resources and infrastructure. Companies include: Merck (Schering Plough), Pfizer (Pharmacy), Achemy (aai), Ipsen (Tercica), Nektar, Titan, Pure Communications and W2O Group.

info@cellandtech.com

BRUCE B.

CONTRACT & ACCESS STRATEGY – SENIOR CONSULTANT

Bruce has in-depth knowledge of the U.S. payer system, contracting/pricing strategies, government pricing, and contract operations. He is familiar with the needs of newly-commercializing enterprises, having started up and built the commercial/government contracting and pricing functions at 4 companies – Abbott Diabetes Care, Oscient, Indevus (now part of Endo Pharmaceuticals), and Insulet. Bruce has also overseen these functions through periods of extreme change at established companies – GE Healthcare (Core Imaging business unit) and Cubist Pharmaceuticals (now part of Merck & Co.).

Bruce also has significant experience in government health policy, and assessing the impacts of policy changes on commercial strategies and operations. His actions in this area include: evaluating the ACA and other federal rules changes to determine requirements, threats, and opportunities (and implementing appropriate changes); serving on PhRMA work groups; and authoring comment letters to CMS on proposed rules changes.

Bruce’s accomplishments also include:

• Devising and executing pricing/contracting strategies across multiple therapeutic classes for both the Rx and acute/institutional markets.
• Determining primary commercial, Medicare, and Medicaid targets for new and in-line products.
• Maintaining government pricing compliance for Medicaid, Medicare Part B, 340B/PHS, and FSS. This includes initiating program participation, adapting to new requirements, and timely reporting/payment.
• Extensive team-building and cross-functional collaboration in start-up and launch settings.
• Establishing executive pricing committees and all supporting procedural governance.
• Contracting and negotiating for trade network formation and third-party logistics (3PL) partnerships.
• Instituting cost-effective solutions for chargeback and rebate operations.

Bruce earned a BA in History from Williams College and an MBA in Marketing and Finance from the Kellogg School of Management at Northwestern University.

info@cellandtech.com

BRAD F.

ACCESS AND BENEFIT DESIGN – SENIOR CONSULTANT

Brad is a highly skilled senior biopharmaceutical industry professional with broad knowledge of the healthcare marketplace and extensive experience in a wide array of marketing and access functions. A strategic, results-oriented industry professional with extensive experience in reimbursement/access, managed markets, account management, contracting, specialty distribution, and product sales, with subject matter expertise in patient access and employer benefit design. Extensive knowledge of the healthcare marketplace with proven ability to develop and execute strategic initiatives with a focus on the value proposition, access, and profitability. Adept at driving business results by successfully leading teams from the initial concept of a project through design, development, communication, training, and implementation. Highly successful at building strong relationships and resolving client issues. Today, Brad specializes in consulting to biopharmaceutical and healthcare companies in the areas of access, reimbursement, launch readiness, value proposition development, payer and distributor strategy, and market access. With more than 35 years of industry experience and leadership, Brad has the ability to work effectively with your staff to help design and implement successful product strategies. Brad’s background includes:

• Over 28 years of experience with Genentech, where he served in a variety of leadership roles in the areas of sales management, reimbursement, and access.
• Established and lead Genentech’s field reimbursement team in 2003, leading the BioOncology reimbursement program. Grew the function from an initial field force of 3 to over 150, supporting multiple brands and therapeutic areas. Developed a clear vision for the field reimbursement function, collaborated with multiple corporate partners including Legal, Government Affairs, brand teams, managed markets and field sales to maximize access to Genentech’s portfolio and establish Genentech as the top-rated reimbursement/access partner in the industry.
• Established the Employer Account Executive team as part of the national Accounts group. Cultivated consultative relationships with key large national employers, employer coalitions, employer benefit consultants and other national organizations. Developed effective strategies for this important customer segment to positively impact benefit design and maximize patient access to the portfolio. Developed/participated in several significant projects, including: NBCH/NCCN Employer Guide to Cancer Treatment and Prevention, The Atlanta Business leaders Initiative, Florida Health Care Coalition Coordinated Oncology Management project.
• Significant Managed Market experience in payer account management, contracting, hospital systems, group purchasing organizations and specialty distribution.
• Prior to joining Genentech, Brad held various positions with Johnson and Johnson and AstraZeneca.

Brad holds a BS in University Studies from the University of New Mexico, where he also did graduate work in Marketing at the Robert O. Anderson School of Business.

info@cellandtech.com

ALAIN G., B.Sc., Grad.D., PMP

COMMERCIAL STRATEGY – SENIOR CONSULTANT

Alain is a commercial executive and life science consultant with deep cross-functional, international experience at a variety of notable firms including Baxalta, Eisai, Schering Plough, Pfizer, and Sanofi. He is an expert in pharmaceutical product launches, having played a leadership role in 14 product launch teams in specialty care, primary care, and rare disease settings. He brings experience in direct oversight of operating budgets and P&L’s in the US, Japan, EU, Canada, and emerging markets and has navigated global matrix organizations through excellent communication and collaboration. Alain is also a PMP (Project Management Professional) certified consultant.

At the global level:

• Held leadership of the global marketing role within Eisai’s Global Neurology BU. Orchestrated the development and deployment of timelines and deliverables for the strategic and tactical plans in support for the global launches of Fycompa (perampanel) in the epilepsy market.
• At Eisai, led the launch planning of a rare disease asset in the treatment of acute thrombocytopenia in a compromised patient population. Additionally, acted as Global Brand Leader (led global and country level plans and execution) for a rare asset in the treatment of Lennox Gastaut Syndrome (infantile seizures).
• At Baxalta, as a launch consultant, initiated and led the planning for the launch of a rare disease asset in the treatment of Acute Leukemia. Post Baxalta acquisition, acted as launch leader for Shire’s oncology group.
• At Pfizer, oversaw the development of global launch planning efforts (timelines and deliverables) for the launch of Lyrica (treatment of fibromyalgia), Torcetrapib/atorvastatin (follow up to Lipitor) as well as roflumilast (asthma/COPD).

At the regional/local level:

• At the regional market level, within Pfizer Canada as Business Unit Leader, led three launches in a span of 18 months (Spiriva, Vfend and Zithromax otitis media 3 day).
• At Schering Plough, led the launch for Nasonex in several emerging markets as well as Japan.
• As consultant to two leading life science organizations, led the development of US strategic and tactical plans in support of rare disease assets in the oncology and neurology markets.

info@cellandtech.com

NEIL G.

MARKET ACCESS & PRICING STRATEGY – SENIOR CONSULTANT

Neil is a pharmaceutical market access specialist with 27 years of experience tracking the global prescription drug and self-medication markets. He has authored more than 150 reports on market access, covering 20 mature and emerging markets, multiple therapeutic areas, and numerous industry issues, including a study on key market access trends in Europe. Neil is an experienced public speaker who has chaired events and delivered numerous presentations at conferences, seminars, webinars and training workshops, including bespoke programmes commissioned by senior executives at top ten pharmaceutical companies.

He is currently working as a consultant and is developing a series of multi-client training programmes in market access. Recent projects include developing an early global pricing strategy for a drug in Phase II clinical trials, stakeholder engagement strategies in preparation for label expansion in a well-established disease area, strategic evaluation of the attractiveness of biosimilar markets, evaluation of payer perceptions and the reimbursement landscape for an innovative companion diagnostic test, assessment of competitor market access strategies for a new oncology drug and a comparative analysis of HTA appraisals in several European markets. Neil previously spearheaded the development of Decision Resources Group’s international market access business, most recently as Vice President of Global Market Access Insights. He has also done contract work on early-stage market access for GlaxoSmithKline.

info@cellandtech.com

ALBERT K., ED.D.

COMMERCIAL STRATEGY – SENIOR CONSULTANT

Albert currently serves as a Senior Consultant. He has an advanced scientific background and completed doctoral studies in the area of applied physiology, with a specialty in lipid metabolism at Columbia University, New York, NY. His clinical research was conducted at the Obesity Research Center under the auspices of Xavier Pi-Sunyer, MD, MPH and Jeanine Albu, MD.

From 2002 to 2007, he was a member of the US Marketing/Commercial leadership team at Amylin Pharmaceuticals, Inc. and collaborated to develop and implement multi-channel go-to-market strategies for the market development and product launch of 2 first-in-class products for the management of type 1 diabetes Symlin® and type 2 diabetes – Byetta®. He has held executive leadership roles with Publicis Health [Chicago, IL and London, United Kingdom] and Huntsworth Health [San Francisco, CA], overseeing multiple healthcare communications agency offices that specialize in the development and implementation of commercialization strategies for market preparation, product launch and life-cycle management [US and global]. During his twenty plus years of experience in the life sciences industry, he was a senior leader of Brand teams to support the clinical development and twelve product launches across the following therapeutic areas [market]

• Cardiovascular [EU]
• Central Nervous System [US and EU]
• Diabetes [US and EU]
• Dermatology [EU]
• Obesity [US]
• Chronic pain [US]
• Rheumatology [US]

Additionally, Albert is an Executive Advisor with the California Life Sciences Institute, an accelerator that provides scientific and commercialization guidance to new and incubator biotech organizations in California.

info@cellandtech.com

JENNIFER L.

COMMERCIAL STRATEGY – SENIOR CONSULTANT

A global brand builder, Jennifer offers a passion for driving business results that has led to her pharmaceuticals, biotechnology, medical devices.

Having both client-side and agency experience, Jennifer has worked on some of the world’s largest brands and for some of the world’s top healthcare companies, including Pfizer, Johnson & Johnson, AstraZeneca, Shire, Regeneron, Novartis, Vertex, GSK, Lundbeck, Merck, Janssen, Sanofi-Aventis, MundiPharma, MSD, Resolute Oncology, Pfizer Consumer Healthcare, Pfizer Animal Health, Zoetis and Renovia. Her category experience includes biosimilars, women’s health, men’s health, cardiovascular, fertility, respiratory, diabetes, CNS, endocrinology, oncology, pain, vaccines, ophthalmology, HIV, haematology, infectious diseases, animal health, and over-the-counter products.

In 2001, Jennifer migrated over to the client side as a marketing director for Pfizer, overseeing strategy, integrated marketing initiatives and innovative platforms for Celebrex, Bextra, and was a key lead in driving the successful launch of Chantix. She then shifted back to the agency side where she helped establish Nitro, later SapientNitro, as an important new digital marketing agency network. Jennifer has supported a variety of teams at Pfizer as a long-term marketing consultant, overseeing strategy, integrated marketing, and sales initiatives for Inflectra, surgical hematology products, Pristiq, Levoxyl, Dilantin, and Caverject Impluse.

Most recently, Jennifer was Chief Marketing Officer at Renovia, a women’s health company, dedicated to delivering innovative new medical devices to help improve pelvic floor health. As a start-up organization, she led market development, integrated marketing and sales efforts, in addition to helping build the Patient Engagement and Care Center.

Jennifer’s career has taken her around the world in executive management roles in the US, the UK, Europe, Asia, the Middle East and Africa. This allows her to bring a holistic, global outline with on-the-ground local insights across all key customers. She brings her broad experience, entrepreneurship, energy, and enthusiasm to each client engagement and brand initiative.

Outside of the office, Jennifer is passionate about building stronger communities, and improving the lives within those communities through the development and execution of long-term sustainability programs.

info@cellandtech.com

MATTHEW W.

PAYER STRATEGY – SENIOR CONSULTANT

Matt has more than 25 years of pharmaceutical experience and has held leadership positions in brand and payer marketing, strategic planning, business development, and healthcare policy. He has worked in market access across all customer segments, providing clients with strategic insights, brand implications and tactical recommendations.

He has extensive experience in specialty and chronic therapeutic areas including distribution, hospitals, IDNs and ACOs in both in pre -launch and launch phases. In addition to his agency experience, Matt was a Product Director at Forest Laboratories, leading managed healthcare business planning and development of strategies for pricing, reimbursement, contracting for all customer segments.

He is a graduate of the State University of New York at Oswego with a Bachelor Degree in Marketing.

info@cellandtech.com

MICHAEL W.

BUSINESS DEVELOPMENT STRATEGY – EXECUTIVE CONSULTANT

Michael is Founder & CFO/COO of an oncolytic immuno-oncology company targeting blood cancers & solid tumors. He previously partnered with ex-Neurocrine drug hunters, orchestrated a $40M series A with top-tier venture investors and established/led operations at Crinetics Pharmaceuticals (NASDAQ: CRNX).

Michael is originally a scientist and trained as a published research scientist (Salk, Cal/HHMI & UCSF), investment banker (Morgan Stanley) and management consultant (Tenet Healthcare). He then spent five years at big pharma (Abbott/Abbvie) rotating through sales, marketing & business development, followed by business development and operations roles of increasing responsibility at both public & private biotechs.

Michael’s key skills include:

• New company creation
• Company leadership, vision & strategic planning
• Board/SAB/advisory board creation & management
• Team-building
• Fundraising with top-tier VCs & other investors
• Strategic finance leadership, planning & management of banks, analysts & investors
• Budgeting, P&L & accounting establishment & leadership
• Business operations establishment & management
• Market research expert & therapeutic pipeline commercial planning
• Sales & marketing (2 blockbuster product launches & top 1% sales award at Abbott/Abbvie)
• Corporate/business development (extensive deal sheet, $1B+ partnership & alliance management)

Michael earned his B.S. in molecular & cell biology, summa cum laude and phi beta kappa, from U.C. Berkeley and M.B.A. in finance & strategy from University of Chicago. He was a member of Cal’s national champion rowing team.

info@cellandtech.com

MICHAEL Y., Ph.D

PRODUCT STRATEGY / R&D – SENIOR DEVICE CONSULTANT

Michael has over 20 years of experience in medical device engineering and clinical science. His successful new product innovation and strategy leadership were proven at large global companies (Johnson & Johnson and St. Jude Medical) as well as mid cap high growth companies (Cardiovascular Systems, Inc and Integra LifeSciences). His expertise ranges from new product design and testing, pre-clinical studies, design review and design transfer, design for manufacturing scale-up, regulatory submission and market release. His engineering training and Six-Sigma applications served him well helping companies with robust manufacturing process development and improvement, achieving significant cost reduction and efficiency increase. He initiated and managed a good number of clinical trials including one of the largest in peripheral artery disease space, Liberty 360. Michael is well versed in product life cycle management, portfolio development and design-to-value engineering throughout his career.

Michael is a proliferate inventor, and has been recognized for his contributions to a variety of product and technology platforms, including interventional cardiology, coronary and peripheral artery disease therapies (drug coated balloon, drug eluting stent, atherectomy), heart arrhythmia management and therapies, pacemaker and ICD, electrophysiology and AF ablation, surgical instruments and tools for neurosurgery, ultrasound tissue ablation, collagen adhesive delivery, and wound closure.

Michael earned a PhD in mechanical engineering from Marquette University.

info@cellandtech.com

JOHN Y., M.SC., PH.D

BUSINESS DEVELOPMENT – SOUTH KOREA

John has more than 10 years of cumulative research & business experience in the pharmaceutical field. He has worked as a business development manager and a technical consultant at MedClaris, Inc. for more than 5 years, developing business leads and managing nonclinical and manufacturing projects from various Korean drug development companies. He is CEO of Atoxlab, Inc. since 2017.

John obtained his Ph.D at the University of Montreal, Canada, studying the pathophysiology of brain injury. During his post-doctoral fellowship at the University of Wisconsin and the National Institute of Health, he researched on the molecular mechanisms and the therapeutic potential of various treatment options for traumatic brain injury using animal models. He has authored or co-authored more than 20 peer-reviewed articles to date, and translated a Korean science-fiction novel to English that is now being sold on Amazon.

info@cellandtech.com